Strategic Initiative

Slingshot members are tracking this corporate initiative:

DURECT (DRRX) and Gilead (GILD) Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Durect will grant Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT's SABER® technology. Gilead also received exclusive access to the SABER® platform for HIV and Hepatitis B Virus (HBV) and the exclusive option to license additional SABER-based products directed to HIV and HBV.
Additional Relevant Details
Under the terms of the agreement, Gilead will make an upfront payment to DURECT of $25 million, with the potential for up to an additional $75 million in development and regulatory milestones, up to an additional $70 million in sales based milestones, as well as tiered royalties on product sales. Gilead has the exclusive option to license additional SABER-based products directed to HIV and HBV for an additional $150 million per product in upfront, development, regulatory and sales based milestones as well as tiered royalties on sales.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jul 22, 2019
Projected Implementation:
Q3, 2019
Relevance Tracked Until:
Q4, 2019
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords License Agreement, Hiv, Investigational New Drug, Saber